Literature DB >> 1824622

Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy.

G Takemura1, H Fujiwara, M Mukoyama, Y Saito, K Nakao, A Kawamura, M Ishida, M Kida, T Uegaito, M Tanaka.   

Abstract

To investigate the ventricular expression of atrial natriuretic peptide (ANP) in human hypertrophic hearts, we conducted an immunohistochemical study of 130 endomyocardial biopsy specimens obtained from the right side of the ventricular septum (RVB), left ventricular free wall (LVB), or both from a total of 80 patients: 44 patients with hypertrophic cardiomyopathy (HCM), 14 with apical hypertrophic cardiomyopathy (APH), 13 with hypertensive hearts (HHD), and nine without hypertrophy (controls). No patients had apparent congestive heart failure. ANP was not seen in ventricular myocytes in controls but was identified in biopsy specimens of hypertrophic hearts, and its distribution was characteristic in each hypertrophic group: 15 RVB (37%) and two LVB (7%) of the HCM group, one RVB (7%) and two LVB (18%) of the APH group, and zero RVB (0%) and five LVB (46%) of the HHD group. Clinical data (including echocardiographic, hemodynamic, and angiographic data) were not directly related to ventricular ANP expression in HCM, APH, or HHD with one exception. In HHD patients, LVB specimens with ANP showed greater ventricular wall thickness than LVB specimens without ANP. According to histological data, however, the ANP-present RVB specimens of HCM or ANP-present LVB specimens of HHD had greater myocyte size than did the ANP-absent specimens. In addition, in HCM patients, the ANP-present RVB specimens showed more severe fibrosis and myofiber disarray than did the ANP-absent specimens. We conclude that a failing state and hemodynamic overload are not likely to be indispensable for ANP expression in human hypertrophic ventricles and that ventricular ANP expression occurs as a response to disease-specific changes: hemodynamic overload in HHD and histological changes such as myocardial fiber disarray, hypertrophy of myocytes, and fibrosis in HCM, which may reflect the characteristic distribution of intraventricular ANP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824622     DOI: 10.1161/01.cir.83.1.181

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy.

Authors:  Elif Elmas; Christina Doesch; Stephan Fluechter; Miriam Freundt; Christel Weiss; Siegfried Lang; Thorsten Kälsch; Dariush Haghi; Jana Papassotiriou; Jan Kunde; Stefan O Schoenberg; Martin Borggrefe; Theano Papavassiliu
Journal:  Int J Cardiovasc Imaging       Date:  2010-09-26       Impact factor: 2.357

2.  Atrial natriuretic factor secretion: a role for atrial systolic ejection force?

Authors:  B Geny; F Piquard; M Follenius; H Petit; F Levy; E Epailly; J G Kretz; B Eisenmann; P Haberey
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

3.  Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies.

Authors:  K Hasegawa; H Fujiwara; K Doyama; M Mukoyama; K Nakao; T Fujiwara; H Imura; C Kawai
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

4.  Constitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by alpha-crystallin-B.

Authors:  Nicolas Bousette; Shaan Chugh; Vincent Fong; Ruth Isserlin; Kyoung-Han Kim; Allen Volchuk; Peter H Backx; Peter Liu; Thomas Kislinger; David H MacLennan; Andrew Emili; Anthony O Gramolini
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

5.  Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts.

Authors:  T Maki; T Horio; F Yoshihara; S Suga; S Takeo; H Matsuo; K Kangawa
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  ANP expression in the hypertensive heart.

Authors:  Gania Kessler-Icekson; Yael Barhum; Jutta Schaper; Wolfgang Schaper; Ella Kaganovsky; Thomas Brand
Journal:  Exp Clin Cardiol       Date:  2002

7.  Myocardial expression of atrial natriuretic factor gene in early stages of hamster cardiomyopathy.

Authors:  P Di Nardo; M Minieri; A Carbone; N Maggiano; R Micheletti; G Peruzzi; G Tallarida
Journal:  Mol Cell Biochem       Date:  1993-08-25       Impact factor: 3.396

8.  Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

Authors:  T Omland; V V Bonarjee; D W Nilsen; J A Sundsfjord; R T Lie; G Thibault; K Dickstein
Journal:  Br Heart J       Date:  1993-11

9.  Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium.

Authors:  K U Knowlton; H A Rockman; M Itani; A Vovan; C E Seidman; K R Chien
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Atrophic cardiomyocyte signaling in hypertensive heart disease.

Authors:  German Kamalov; Wenyuan Zhao; Tieqiang Zhao; Yao Sun; Robert A Ahokas; Tony N Marion; Fahed Al Darazi; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2013-12       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.